Insider · CIK 0001341125
Richard Kuntz
Files at INVE (Identiv, Inc.), DMAC (DiaMedica Therapeutics Inc.), ZIMV (ZimVie Inc.). First filing -, latest -.
Richard Kuntz files SEC Form 4 as director at INVE (Identiv, Inc.), and also at DMAC (DiaMedica Therapeutics Inc.), ZIMV (ZimVie Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Richard Kuntz has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +40,412 | $0.00 | $0 | 40,412 | Jun 3, 2026 |
| Oct 20, 2025 | ZIMV ZimVie Inc. | DDisposition to issuer Deferred Share Unitsderivative | -13,073 | - | - | 0 | Oct 20, 2025 |
| Oct 20, 2025 | ZIMV ZimVie Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -57,728 | - | - | 0 | Oct 20, 2025 |
| Sep 30, 2025 | ZIMV ZimVie Inc. | AGrant or award Deferred Share Unitsderivative | +662 | $0.00 | $0 | 13,073 | Oct 2, 2025 |
| Jul 29, 2025 | INVE Identiv, Inc. | AGrant or award Common Stock | +21,148 | $0.00 | $0 | 48,168 | Jul 31, 2025 |
| Jun 30, 2025 | ZIMV ZimVie Inc. | AGrant or award Deferred Share Unitsderivative | +1,341 | $0.00 | $0 | 12,411 | Jul 2, 2025 |
| Jun 1, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +32,162 | $0.00 | $0 | 32,162 | Jun 3, 2025 |
| May 7, 2025 | ZIMV ZimVie Inc. | AGrant or award Deferred Share Unitsderivative | +500 | $0.00 | $0 | 11,070 | May 9, 2025 |
| May 7, 2025 | ZIMV ZimVie Inc. | AGrant or award Restricted Stock Unitsderivative | +21,119 | $0.00 | $0 | 57,728 | May 9, 2025 |
| Mar 31, 2025 | ZIMV ZimVie Inc. | AGrant or award Deferred Share Unitsderivative | +1,163 | $0.00 | $0 | 10,570 | Apr 2, 2025 |
| Jan 2, 2025 | DMAC DiaMedica Therapeutics Inc. | AGrant or award Voting Common Shares, no par value per share | +9,925 | $5.34 | $53k | 24,210 | Jan 3, 2025 |
| Dec 31, 2024 | ZIMV ZimVie Inc. | AGrant or award Deferred Share Unitsderivative | +895 | $0.00 | $0 | 9,407 | Jan 3, 2025 |
| Jul 29, 2024 | INVE Identiv, Inc. | AGrant or award Common Stock | +14,773 | $0.00 | $0 | 27,020 | Oct 23, 2024 |
Questions about Richard Kuntz
Answered from the filings on this page, as of the latest one.
Is Richard Kuntz buying or selling?
Richard Kuntz has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Richard Kuntz's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Richard Kuntz has 0.
Where does Richard Kuntz file Form 4?
Richard Kuntz has filed Form 4 at INVE (Identiv, Inc.); DMAC (DiaMedica Therapeutics Inc.); ZIMV (ZimVie Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.